FDA Issues Untitled Letter to Alar Pharmaceuticals Over Promotion of Unapproved Ketamine Drug ALA-3000
核心洞察
The FDA's Office of Prescription Drug Promotion issued an Untitled Letter to Alar Pharmaceuticals (搜索) on August 21 over promotional materials for ALA-3000, an investigational ketamine pamoate (搜索) injection for treatment-resistant depression (搜索).
The agency found that exhibit booth and brochure materials at the American Psychiatric Association's May 2026 annual meeting portrayed ALA-3000 as safe and effective despite lacking FDA approval.
FDA flagged claims including "No abuse signals" and elimination of mandatory post-dose monitoring, noting ketamine is a Schedule III controlled substance with serious associated risks.
The US Food and Drug Administration (FDA) has issued an Untitled Letter to Alar Pharmaceuticals (搜索), accusing the company of making misleading claims about the safety and effectiveness of ALA-3000 (ketamine pamoate (搜索)), its investigational new drug for treatment-resistant depression (搜索) (TRD). The letter, issued on August 21 by the FDA's Office of Prescription Drug Promotion (OPDP), marks the first such enforcement action in over a month and the 21st untitled letter issued this year by OPDP addressing illegal prescription drug advertising.
The agency determined that materials available at Alar's exhibit booth and a brochure distributed at the American Psychiatric Association's annual meeting — held from May 16 to May 20 in San Francisco — crossed the line from scientific discussion into promotion of an unapproved drug. According to the letter, "The exhibit booth display and the brochure make conclusory representations in a promotional context regarding the safety and efficacy of ALA3000, an investigational new drug that has not been approved by FDA and whose safety and efficacy have not been established."
Claims Flagged by the FDA
OPDP took issue with several specific statements in the exhibit and brochure, including that ALA-3000 "Breaks Key Barriers in Ketamine Therapy for TRD," produced "No overall sedative, dissociative, psychosis-like side effects," and showed "No abuse signals." Other concerning claims cited by the agency included "No sedation, dissociation, psychosis-like effects, or commonly ketamine-reported AEs (e.g., blood pressure elevation, urinary toxicity)" and that the drug "Potentially eliminates the mandatory ≥2-hour post-dose on-site monitoring required with ketamine therapies."
The brochure also described a "Sustained-release profile for weeks without pronounced initial burst or dose dumping effect." The FDA stated these claims "are extremely concerning given the lack of adequate safety and efficacy data for ALA-3000," and that the materials represented in a promotional context that ALA-3000 is different from or superior to approved therapies for treating TRD.
Regulatory and Public Health Concerns
The agency emphasized the public health implications of these claims, noting that ketamine, the active ingredient in ALA-3000, is a Schedule III (CIII) controlled substance associated with serious risks including sedation, dissociation, respiratory depression, hemodynamic instability leading to increased blood pressure, as well as potential abuse and misuse.
The FDA also reprimanded Alar for failing to disclose that ALA-3000 is an investigational new drug that has not received approval for commercial distribution in the US. Regulators noted that the exhibit display did not include information indicating the drug's investigational status, and that the booth was situated in the APA exhibit hall near booths for approved products. The brochure appeared to indicate that the investigational drug had only been studied in Phase 1 clinical trials.
Consequently, the FDA concluded that ALA-3000 is misbranded under section 502(f)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and in violation of section 301(a) of the FD&C Act.
Context and Enforcement Trends
Ketamine was approved as a general anesthetic by the FDA in 1970. More recently, the agency approved Spravato (esketamine), a ketamine derivative nasal spray used to treat adults with TRD and those with depressive symptoms in major depressive disorder (搜索) with acute suicidal ideation or behavior, alongside an oral antidepressant.
The Alar letter is the latest in a string of OPDP enforcement actions this year, with untitled letters issued to companies including Sanofi, Viatris, Lundbeck, Bayer, Pfizer and Novo Nordisk in 2026. Notably, the FDA issued an Untitled Letter in November concerning a ketamine product, when OPDP dinged PharmaTher for a generic ketamine product whose webpage misrepresented the drug's approved uses.
Company Response and Next Steps
Notably, the FDA redacted the name and other identifying information of the Alar representative to whom it addressed the letter, referring only to the recipient as the company's "authorized representative." This breaks from the agency's standard operating procedure for other recent OPDP Untitled Letters, which have publicly named the individuals receiving them.
Alar Pharmaceuticals (搜索) did not immediately respond to a request for comment. The FDA has given the company 15 working days after receiving the letter to identify other ALA-3000 promotional materials containing similar representations and explain how it plans to discontinue them, or to provide its reasoning and supporting evidence if it disputes the FDA's findings.